The psychedelic sector never sits still. Here is what happened during the week of March 23–29, 2026, and why each story matters for the companies and investors we track.
Numinus Wellness Inc. (NUMI): Numinus faces TSX delisting, applies to list on the CSE
Numinus said the Toronto Stock Exchange's continued listing committee decided to delist its shares, effective April 22, 2026, and that the company has applied to list on the Canadian Securities Exchange instead. The update followed a broader restructuring in which Numinus sold its U.S. wellness clinics and narrowed its focus to a clinical trial site network and practitioner training platform. Management said it continues to evaluate financings, partnerships and potential M&A to shore up its balance sheet.
Source: newsfilecorp.com
Compass Pathways plc (CMPS): Compass reports 2025 results, says cash runway extends into 2028
Compass Pathways reported fourth-quarter and full-year 2025 results, with 2025 R&D expense roughly flat at $118.4 million and G&A of $60.6 million. The company said a February financing of about $150 million plus roughly $200 million from warrant exercises pushed its cash runway into 2028. Management pointed to an upcoming FDA meeting to confirm its NDA strategy for COMP360 psilocybin and reiterated a goal of being launch-ready by the end of 2026.
Source: businesswire.com
GH Research PLC (GHRS): GH Research publishes GH001 Phase 2b depression data in JAMA Psychiatry
GH Research announced that full results from its randomized, placebo-controlled Phase 2b trial of inhaled mebufotenin (GH001, a 5-MeO-DMT formulation) in treatment-resistant depression were published in JAMA Psychiatry. The peer-reviewed data reinforced a rapid, large treatment effect one week after dosing, and the company highlighted a new finding that efficacy appeared independent of the number of prior antidepressant failures. The publication supports GH Research's push toward a global Phase 3 program in TRD.
Source: globenewswire.com
Transcend Therapeutics / Otsuka Pharmaceutical: Otsuka to acquire methylone developer Transcend Therapeutics for up to $1.225 billion
Japan's Otsuka Pharmaceutical agreed to acquire privately held Transcend Therapeutics, paying $700 million at closing plus up to $525 million in sales-based milestones, for total potential consideration of about $1.225 billion. Transcend's lead asset is TSND-201 (methylone), a rapid-acting neuroplastogen with FDA Breakthrough Therapy designation being developed for PTSD, with Phase 2 data published in JAMA Psychiatry in February 2026. The deal, expected to close in Q2 2026, is one of the largest strategic acquisitions in the psychedelic-adjacent space and signals big-pharma appetite for the sector.
Source: otsuka.co.jp
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.